Gilberto Chéchile Toniolo¹, Nuria Jornet^1,*, Jady Rojas¹, Natalia Tejedor¹, Santiago Carrara¹, Alicia Maccagno², Teresa Brufau¹

Canadian Journal of Urology, Vol.33, No.1, pp. 93-103, 2026, DOI:10.32604/cju.2026.069182 - 28 February 2026

Abstract Background: Low-dose rate (LDR) prostate brachytherapy is a recommended treatment of localized prostate cancer in current guidelines. The study aimed to determine biochemical relapse-free survival (BRFS) in patients treated with dynamic real-time low-dose rate (LDR) brachytherapy using Iodine 125 (I¹²⁵). Methods: We retrospectively reviewed 499 patients with localized prostate cancer treated with I¹²⁵ LDR real-time brachytherapy between 2003 and 2021. The mean patient age was 65 years (range: 45–84 years). Based on the National Comprehensive Cancer Network (NCCN) risk classification, 230 patients (46.1%) were categorized as low risk, 235 (47.1%) as intermediate risk, and 34 (6.8%)… More >

Skander Zouari^1,*, Flora Barthe¹, Arnoult Morrone¹, Lionel Mendel², Imad Bentellis², Louis Vignot¹, Romain Haider¹, Younes Ahallal¹, Daniel Chevallier¹, Matthieu Durand^1,3

Canadian Journal of Urology, Vol.33, No.1, pp. 173-184, 2026, DOI:10.32604/cju.2025.064281 - 28 February 2026

Abstract Background: Inflatable Penile Prosthesis (IPP) is the treatment for erectile dysfunction (ED) refractory to pharmacological therapies. Long-term data on factors associated with prosthesis survival remain unclear. This study aimed to analyze the long-term survival of penile prostheses and identify risk factors associated with survival without reintervention. Methods: This is a retrospective, single-center study of patients who underwent IPP implantation between January 2014 and December 2022. Preoperative data related to the patient and the etiology of ED, as well as perioperative data, were collected. The primary outcome was survival without reintervention, defined as prosthesis revision or… More >

Thomas Kidu¹, Harini Kethar², Haben Gebrekidan³, Haleem Farman⁴, Ahmed Sedik^4,5, Walid El-Shafai^6,7, Jawad Khan^8,*

CMES-Computer Modeling in Engineering & Sciences, Vol.146, No.2, 2026, DOI:10.32604/cmes.2026.076798 - 26 February 2026

Abstract Colorectal cancer is the third most diagnosed cancer worldwide, and immune checkpoint inhibitors have shown promising therapeutic outcomes in selected patient groups. This study performed a comprehensive analysis of multi-omics data from The Cancer Genome Atlas colorectal adenocarcinoma cohort (TCGA-COADREAD), accessed through cBioPortal, to develop machine learning models for predicting progression-free survival (PFS) following immunotherapy. The dataset included clinical variables, genomic alterations in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS), B-Raf Proto-Oncogene (BRAF), and Neuroblastoma RAS Viral Oncogene Homolog (NRAS), microsatellite instability (MSI) status, tumor mutation burden (TMB), and expression of immune checkpoint genes. Kaplan–Meier… More >

Ina Shehaj^1,2,*, Slavomir Krajnak¹, Katrin Almstedt¹, Yaman Degirmenci¹, Roxana Schwab¹, Kathrin Stewen¹, Walburgis Brenner¹, Annette Hasenburg¹, Marcus Schmidt^1,#, Anne-Sophie Heimes^1,#

Oncology Research, Vol.34, No.3, 2026, DOI:10.32604/or.2025.072222 - 24 February 2026

Abstract This article has no abstract. More >

Leenah Abdulgader¹, Abdullah Esmail^2,*

Oncology Research, Vol.34, No.3, 2026, DOI:10.32604/or.2026.069227 - 24 February 2026

Abstract Unresectable hepatocellular carcinoma (HCC) remains a global challenge, with limited effective treatment options for advanced-stage disease. The HIMALAYA trial (phase III randomized study that evaluated the STRIDE regimen) introduced the Single Tremelimumab Regular Interval Durvalumab (STRIDE) regimen, an immunotherapy-based approach that achieved a median overall survival (OS) of 16.43 months compared to 13.77 months with sorafenib. While statistically significant, this ~2.7 months OS gain warrants scrutiny in light of STRIDE’s increased immune-related toxicity and cost. This commentary evaluates STRIDE’s impact within the broader landscape of first-line systemic therapy for unresectable HCC, alongside other regimens such… More >

Enrique Oropeza-Maetínez¹, Eva G. Palacios-Serrato¹, Marina Macías-Silva², Angeles C. Tecalco-Cruz^1,*

European Cytokine Network, Vol.36, No.3, pp. 38-51, 2025, DOI:10.1684/ecn.2025.0503 - 28 February 2026

Abstract Background: Glioblastoma is a lethal primary brain tumor that is therapeutically challenging due to its rapid progression. Interferon-gamma (IFN-γ) signaling is altered in glioblastoma. Moreover, proteolytic enzymes, known as proteases, have been linked to the invasive growth of cancerous cells. In this study, we aimed to identify a glioblastoma-associated protease group and to determine its potential connection with IFN-γ signaling. Methods: Using cancer expression databases, we analyzed the differential expression of 35 proteases in glioblastoma and healthy brain tissue, and the relevance of their deregulation to patient survival. We also explored correlations between IFN-γ signaling… More >

Mohammed Majid Abed^1,2,*, Murat Aydin¹, Esma Yiğider¹, Melek Ekinci³, Ertan Yildirim³

Phyton-International Journal of Experimental Botany, Vol.94, No.12, pp. 3845-3860, 2025, DOI:10.32604/phyton.2025.073163 - 29 December 2025

Abstract Plants are continuously exposed to abiotic and biotic stresses that threaten their growth, reproduction, and survival. Adaptation to these stresses requires complex regulatory networks that coordinate physiological, molecular, and ecological responses. However, such adaptation often incurs significant costs, including reduced growth, yield penalties, and altered ecological interactions. This review systematically synthesizes recent advances published between 2018 and 2025, following PRISMA criteria, on plant responses to abiotic and biotic stressors, with an emphasis on the trade-offs between adaptation and productivity. It also highlights major discrepancies in the literature and discusses strategies for enhancing plant stress tolerance More >

Abdul Baseet Arham¹, John M. Rieth², Michael A. O’Donnell^3,*

Canadian Journal of Urology, Vol.32, No.6, pp. 605-620, 2025, DOI:10.32604/cju.2025.063632 - 30 December 2025

Abstract Background: Genitourinary (GU) sarcomas are rare soft tissue malignancies, comprising around 2% of all GU cancers. Due to their rarity, limited data exist on optimal management and long-term outcomes. This study presents a 25-year single-institution experience, evaluating clinical presentation, treatment strategies, and survival outcomes, aims to identify trends over time and potential predictors of prognosis. Methods: A retrospective review was conducted of patients aged ≥18 years diagnosed with GU sarcomas at the University of Iowa Hospitals and Clinics (1998–2023). Data on tumor subtype, staging, histopathology, treatment modalities, and survival outcomes were analyzed. Kaplan-Meier analysis estimated… More >

Manzhu Liao¹, Lan Yang¹, Liehua Tie¹, Qiqiang Guo^1,*, Weilie Zheng^2,*, Jiangrong Li², Yongxia Li²

Phyton-International Journal of Experimental Botany, Vol.94, No.11, pp. 3633-3652, 2025, DOI:10.32604/phyton.2025.072725 - 01 December 2025

Abstract Cupressus gigantea is an endemic endangered tree species in the Tibet Plateau, and studying the survival status of the different C. gigantea populations and revealing the main environmental factors that affect the population survival are particularly significant for the conservation and sustainable development of endangered species. Based on the 28 sample plots, the Hierarchical Cluster Method was used to classify the C. gigantea populations into four community types. Age structure diagrams were drawn based on the structure of each community, static life tables and survival curves were compiled, and the future development trends of each age group in… More >

Hui Yi^1,2,#, Hongjian Shi^2,3,#, Fuquan Kan^2,4,#, Fan Han², Lei Wan⁵, Xiaoyang Hong¹, Zhe Zhao¹, Junjie Shao², Gang Wang¹, Hui Wang¹, Hua Yan⁵, Xiujuan Shi¹, Ran Zhang^2,6,*, Gengxu Zhou^1,*

Congenital Heart Disease, Vol.20, No.4, pp. 519-530, 2025, DOI:10.32604/chd.2025.067164 - 18 September 2025

Abstract Background: To investigate the impact of preoperative extracorporeal membrane oxygenation (ECMO) on clinical outcomes in pediatric heart transplantation (PHT). Methods: This retrospective cohort analysis was conducted on 19 pediatric heart transplant recipients, divided into two groups: ECMO and non-ECMO, based on whether preoperative ECMO was utilized. We evaluated the patients’ surgical conditions, postoperative complications, and survival rates. Additionally, the analysis focused on the differences and correlations in clinical characteristics, inflammatory markers, and long-term survival outcomes. Results: There was no statistically significant difference in perioperative survival rates between the ECMO group (85.7%) and the non-ECMO group (83.3%). However,… More >